Gilead Sciences
Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma
Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25
Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes
Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology
Shoreline Biosciences Reduces Staff Amid Uncertainty in Partnership with Gilead’s Kite
Shoreline Biosciences, Gilead Sciences, Kite Pharma, layoffs, cell therapy, strategic partnership
Terray Therapeutics and Gilead Sciences Collaborate on AI-Driven Drug Discovery to Accelerate Small Molecule Therapies
AI-driven drug discovery, Terray Therapeutics, Gilead Sciences, Small molecule therapies, tNova platform, High-throughput experimentation, Generative AI, Strategic collaboration
EMA Supports Approval of Gilead’s Liver Disease Drug from $4.3B CymaBay Acquisition
Gilead Sciences, CymaBay Therapeutics, seladelpar, primary biliary cholangitis (PBC), liver disease, EMA approval, $4.3 billion deal
Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp
Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry
Gilead CEO Daniel O’Day Welcomes Former Colleague Dietmar Berger as New Chief Medical Officer
Daniel O’Day, Gilead Sciences, Dietmar Berger, Sanofi, Chief Medical Officer, Oncology
Gilead Partners with Tubulis to Revitalize ADC Pipeline
Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership
Gilead Sciences Acquires Investigational HIV Vaccine Assets from AELIX Therapeutics
Gilead Sciences, AELIX Therapeutics, HIV vaccine, HTI immunogen, IrsiCaixa, HIVACAT program
Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office
Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction